Please assess the completion status of the following clinical trial:

Trial Title: Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has been correctly informed~* The patient must have given his/her informed and signed consent.~* The patient must be insured or beneficiary of a health insurance plan.~* The patient is at least 18 years old and less than 75 years old~* Probable, or laboratory-supported probable or definite ALS as defined by El Escorial Revised ALS diagnostic criteria (according to Airlie House Conference 1988)~* Stable on riluzole treatment for more than 3 months with liver function test results \< 2ULN~* Disease duration ≤ 5 years~* Vital capacity ≥ 70% of normal~* Ability to swallow without the requirement for nasogastric or PEG feeding~* Agreement for patient to use an adequate method of contraception throughout the study and for 2 weeks after post study visit~* The patient is available and willing to participate in seven study visits occurring at the CHU within the next six months~Exclusion Criteria:~* The patient is participating in another interventional study~* Within the past three months, the patient has participated in another interventional~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection~* The patient is an adult under guardianship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* Other life threatening disease~* Presence of contra-indicated concomitant treatments or with potential neuroprotective benefit (see section 11.2 of the protocol)~* Presence of tracheostomy or non-invasive ventilation~* Use of Percutaneous endoscopic gastrostomy (PEG) or nasogastric tube~* Presence of clinical infection (treated or untreated)~* Positive serology for CMV, EBV (confirmed by viral load), or HIV~* Vaccination within 8 weeks prior to first experimental dosing~* Other disease precluding functional assessments~* Cancer within the past 5 years (except stable non-metastatic basal cell skin carcinoma or in situ carcinoma of the cervix)~* Severe cardiac or pulmonary disease~* Documented auto-immune disorders except asymptomatic Hashimoto thyroiditis~* Women of child bearing age without contraception or pregnant or breast feeding~* Any clinically significant laboratory abnormality (excepting cholesterol, triglyceride and glucose)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: Placebo
- 1.0 IL-2 (Type: EXPERIMENTAL): Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 1.0 MIU IL-2 per day
- 2.0 IL-2 (Type: EXPERIMENTAL): Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 2.0 MIU IL-2 per day

Based on this trial design, predict the completion outcome and termination type (if applicable).